APA (7th ed.) Citation
Easaw, J. C., Lim, H. J., Karachiwala, H., Gill, S., Zhu, X., & Bateman, J. (2025). Zolbetuximab or Immunotherapy as the Initial Targeted Therapy in CLDN18.2-Positive, HER2-Negative Advanced Gastric Cancer: Weighing the Options. Current Oncology, 32(11), 648-660.
Chicago Style (17th ed.) Citation
Easaw, Jacob C., Howard J. Lim, Hatim Karachiwala, Sharlene Gill, Xiaofu Zhu, and Justin Bateman. "Zolbetuximab or Immunotherapy as the Initial Targeted Therapy in CLDN18.2-Positive, HER2-Negative Advanced Gastric Cancer: Weighing the Options." Current Oncology 32, no. 11 (2025): 648-660.
MLA (9th ed.) Citation
Easaw, Jacob C., et al. "Zolbetuximab or Immunotherapy as the Initial Targeted Therapy in CLDN18.2-Positive, HER2-Negative Advanced Gastric Cancer: Weighing the Options." Current Oncology, vol. 32, no. 11, 2025, pp. 648-660.
Warning: These citations may not always be 100% accurate.